Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07808073) titled 'A Study of LY4329090 in Participants With Obesity or Overweight Who Are Otherwise Healthy' on Sept. 3.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Basic Science. Masking: Double (Participant, Investigator).
Primary Sponsor: Eli Lilly and Company
Condition:
Obesity
Overweight
Intervention:
Drug: LY4329090
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: September 2026
Target Sample Size: 184
Countries of Recruitment:
United States
Singapore
United States
To know more, visit https://clinicaltrials....